Latest - HIV/AIDS

• Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?   CCR5- delta 32 mutation homozygosity is associated with increased mortality but may lead to a potential cure for HIV. Is it worth the risk?
  Medscape HIV/AIDS, July 2019
• Risk Factors for Antiretroviral Therapy Discontinuation Which HIV patients may be more likely to discontinue ART? Learn about the factors that may predict treatment interruptions.
  AIDS, July 2019
• Tooth Wear in Patients Treated With ART for HIV People living with HIV have an increased incidence of poor oral health. Do antiretroviral medications used in HIV treatment increase bruxism and negatively impact tooth wear?
  BMC Oral Health, July 2019
• Universal Test and Treat Won't Stop HIV Epidemic In recent years, 3 large studies tested the idea that scaling up HIV testing and offering treatment immediately might halt new infections. Researchers grapple with whether test-and-treat is enough.
  Medscape Medical News, July 2019
• U.N. Wants More Urgency in AIDS Fight as Gains and Funding Fade The global fight against AIDS is stalling due to lower investment, marginalized communities missing vital health services, and new HIV infections rising in some parts, the United Nations warned on Tuesday.
  Reuters Health Information, July 2019
• IAS 2019The New Face of HIV and Treating the 'Hardly Reached' As the world's biggest HIV conference approaches, researchers, drug companies, and public agencies are questioning whether the clinical trial designs they've always used will actually end the epidemic.
  Medscape Medical News, July 2019
• Parenteral Drug Use and HCV Treatment Uptake in HIV Patients A new study identifies parenteral drug use as a contributing factor to low HCV treatment uptake among HIV-infected patients.
  HIV Medicine, July 2019
• IAS 2019 Read clinically focused news coverage of key developments from IAS 2019
  Medscape HIV/AIDS, July 2019
• Variations in HIV Testing Rates in the US, 2016-2017 This analysis found that less than 40% of U.S. adults have ever been tested for HIV. Do certain areas have lower testing rates than others?
  Morbidity & Mortality Weekly Report, July 2019
• GSK's Two-Drug HIV Dovato Treatment Meets Main Goal in Study GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.
  Reuters Health Information, July 2019
• Primary Health Care: An Opportunity for Undiagnosed HIV Primary care providers could play an important role in the early identification of undiagnosed HIV infection.
  HIV Medicine, July 2019
• Pregnancy and Neonatal Outcomes After Dolutegravir Exposure What have we learned about the safety of dolutegravir exposure during pregnancy?
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, July 2019
• Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV Implementation of dolutegravir (DTG)-containing antiretroviral therapy (ART) regimens for adolescents in Zimbabwe may require additional drugs and surveillance for drug resistance mutations (DRMs), researchers say.
  Reuters Health Information, July 2019
• Alert European Commission Greenlights Drug-Sparing Dovato for HIV Dovato (dolutegravir and lamivudine), a single-pill, two-drug regimen taken once daily, is noninferior to a three-drug regimen for treatment-naïve adults and children older than 12 with HIV in Europe.
  International Approvals, July 2019
• Development of TB During Treatment of Head and Neck Carcinoma This case series suggests that patients with head and neck carcinoma are at high risk of developing tuberculosis.
  Journal of Medical Case Reports, July 2019
• Neural Tube Defects After Raltegravir During Pregnancy Is there an association between raltegravir exposure during pregnancy and the development of neural tube defects?
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, July 2019
• Flu Shot Weak This Season, Recs for Catch-up HPV Vaccines: CDC A CDC advisory panel stated that this past season's flu vaccine was only about 30% effective, while recommending a decision-making process for those aged 27 to 45 years to get catch-up vaccinations for HPV.
  Medscape Medical News, June 2019
• Many in the United States Have Not Been Tested for HIV The findings represent a 'missed opportunity' to fully execute HIV screening recommendations, CDC researchers said.
  Medscape Medical News, June 2019
• HIV Patients Spend More Time on Kidney Transplant Waiting List HIV-positive patients who need a new kidney have delayed referral to transplant programs and spend more time on the waitlist, according to preliminary data from two independent studies presented June 4 at the American Transplant Congress in Boston.
  Reuters Health Information, June 2019
• Using Social Media to Increase HIV Testing Among MSM An online campaign in China demonstrates that social media platforms can be utilized effectively to increase HIV testing in men who have sex with men, traditionally a difficult group to reach.
  Morbidity & Mortality Weekly Report, June 2019